Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients.

Arno's lead clinical development compound is AR-67, a novel, third-generation camptothecin analogue, which is expected to enter Phase II studies during the first half of 2009 in patients with glioblastoma multiforme, or GBM, a highly aggressive form of brain cancer. Arno also anticipates initiating a Phase II study in patients with myelodysplastic syndrome, or MDS, a group of diseases marked by abnormal production of blood cells by the bone marrow. AR-12 is a potential first-in-class, orally available PI3-k/Akt inhibitor that has completed IND-enabling studies. AR-42 is an orally available, targeted inhibitor of the Pan-DAC and Akt pathways that received FDA acceptance of its IND in the first quarter of 2009.